Among other targets, it inhibits BCR-Abl (breakpoint cluster region–Abelson murine leukemia) and is, therefore, used in the treatment of chronic myelogenous leukemia (CML) that is associated with the Philadelphia chromosome [30]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.